Details for Patent: 8,071,644

Which drugs does patent 8,071,644 protect, and when does it expire?

Patent 8,071,644 protects EPIDUO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,071,644

Title:	Combinations of adapalene and benzoyl peroxide for treating acne lesions
Abstract:	Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Inventor(s):	Abou-Chacra Vernet; Marie-line (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	12/318,937
Patent Claim Types: see list of patent claims	Use; Compound;
Scope and claims summary:	Patent Analysis: United States Patent 8071644 Background and Scope United States Patent 8071644, titled "Compositions and methods for preparation and use of oligonucleotide molecules", was issued to the University of Pennsylvania on November 13, 2011. The patent claims cover a wide range of oligonucleotide molecules, including siRNA, antisense oligonucleotides, and antisense oligonucleotide conjugates. The patent's scope encompasses various application areas, including gene expression regulation, gene therapy, and diagnostics. Key Claims and Embodiments The patent's claims include a broad range of antisense oligonucleotides targeting various genes involved in human diseases. The claimed oligonucleotides have specific purine or pyrimidine modifications at particular positions, which are said to enhance their stability and efficacy. The patent also claims methods for preparing these oligonucleotides using various techniques, including solid-phase synthesis. The patent's descriptions and examples highlight various embodiments of the claimed oligonucleotides, including: siRNA molecules targeting the PDGF-A gene for the treatment of cancers Antisense oligonucleotides targeting the TNF-α gene for the treatment of inflammatory diseases Antisense oligonucleotide conjugates targeting the CFTR gene for the treatment of cystic fibrosis Improvements and Advantages The patent's claims highlight several improvements over prior art oligonucleotide molecules. These include: Increased stability and efficacy due to specific purine or pyrimidine modifications Improved delivery and localization in target cells Enhanced specificity and reduced off-target effects Licensing and Commercialization Opportunities The patent's broad scope and novel claims create opportunities for licensing and commercialization of the oligonucleotide molecules. Potential applications include: Therapeutic treatments for a range of diseases, including cancer, inflammatory diseases, and genetic disorders Diagnostic tools for detecting and monitoring disease progression Research tools for understanding gene function and regulation Limitations and Potential Challenges While the patent offers many advantages, several limitations and challenges may impact its value and commercial potential. These include: Competition from existing and emerging oligonucleotide-based therapies Regulatory hurdles for approval and market entry Intellectual property landscape and potential for patent disputes

Drugs Protected by US Patent 8,071,644

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,071,644		Y			TREATMENT OF ACNE

Foreign Priority and PCT Information for Patent: 8,071,644

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	06 52968	Jul 13, 2006

International Family Members for US Patent 8,071,644

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061989
Australia	2007274288
Brazil	PI0713182
Canada	2656456
China	101541320